Express News | Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic Adi Platform, Advancing Toward First-in-Human Clinical Trials

ReutersDec 12 08:15 ET

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement With Aditxt, Inc.

GlobeNewswireNov 19 07:17 ET

Appili Therapeutics Inc: INTERIM MDA EN

SEDARNov 14 08:27 ET · Announcements

Appili Therapeutics Inc: INTERIM FINANCIAL STATEMENTSREPORT EN

SEDARNov 14 08:27 ET · Announcements

Express News | Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

ReutersNov 14 07:15 ET

Express News | Aditxt Provides Update on Equity Line of Credit, Atm Usage, and Outstanding Number of Shares

ReutersNov 8 08:31 ET